ACC.14: ACC unveils list of late-breakers

The American College of Cardiology (ACC) released its lineup of late-breaking clinical trials to be presented at the scientific sessions March 29-31 in Washington, D.C.

Here they are by date:

Saturday, March 29

  • Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
  • Main Results of SYMPLICITY HTN-3

Sunday, March 30

The first five presentations are part of a joint session of the ACC and JAMA.

  • Effect of Inhibition of Lipoprotein-Associated Phospholipase A2 with Darapladib on Ischemic Events in Patients with Chronic Coronary Heart Disease: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) Trial
  • The Low-density Lipoprotein Cholesterol Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy - 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
  • Evaluation of the Dual PPAR-α/γ Agonist Aleglitazar to Reduce Cardiovascular Events in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus: the AleCardio Trial
  • Two-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the NOBORITM Biolimus-Eluting versus XIENCETM/PROMUSTM Everolimus-eluting Stent Trial (NEXT)
  • A Phase 3 Double-blind, Randomized Study to Assess the Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin
  • Efficacy And Safety Of Colchicine In Patients With Multiple Recurrences Of Pericarditis: Results of A Multicenter, Double-blind, Placebo-controlled, Randomized Study (corp-2 Trial)
  • The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation in Real World Patients with Uncontrolled Hypertension
  • One Year Follow-up of the Melody Transcatheter Pulmonary Valve Multicenter Post Approval Study
  • Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure
  • Negative High-Sensitive Troponins in the Emergency Department and Risk of Myocardial Infarction

Monday, March 31

The first five presentations are part of a joint session of the ACC and the New England Journal of Medicine.

  • The Impact of Acetyl-Salicylic Acid on Major Arterial and Venous Complications in Patients Undergoing Noncardiac Surgery
  • A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery (POISE 2)
  • Steroids in Cardiac Surgery Trial (SIRS)
  • Metformin in Acute Myocardial Infarction
  • Effect of Bariatric Surgery vs. Intensive Medical Therapy on Long-term Glycemic Control and Complications of Diabetes: 3-Year STAMPEDE Trial Results
  • One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
  • A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement - The CHOICE Trial
  • Unfractionated Heparin versus Bivalirudin in Primary Percutaneous Coronary Intervention: A Unique Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Designed to Reflect Real-World, Contemporary Practice
  • Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial
  • Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial
Candace Stuart, Contributor

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.